1)髙田菜月・他:本態性血小板血症を合併した下咽頭癌例.耳鼻臨床111:207-211,2018
2)Srour SA, et al:Incidence and patientsurvival of myeloproliferative neoplasms and myeloproliferative neoplasms in the United States, 2001-12. Br J Haematol 174:382-396, 2016
3)荒木真理人・他:骨髄増殖性腫瘍の遺伝子変異.臨血57:2526-2534,2016
4)Tefferi A, et al:Polycythemia vera and essential thrombocythemia:2017 update on diagnosis, risk-satisfaction, and management. Am J Hematol 92:94-108, 2017
5)Cortelazzo S, et al:Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 8:556-562, 1990
6)Fenaux P, et al:Clinical course of essential thrombocythemiain 147 cases. Cancer 66:549-556, 1990
7)Tefferi A, et al:A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc 76:22-28, 2001
8)Elliot MA, et al:Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 128:275-290, 2005
9)Michiels JJ, et al:The myeloproliferative disorders. An historical appraisal and personal experiences. Leuk Lymphoma 22:1-14, 1996
10)Arber DA, et al:The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391-2405, 2016
11)日本血液学会(編):造血器腫瘍診療ガイドライン2018年版補訂版.金原出版,東京,2020
12)Barbui T, et al:Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J 5:e369, 2015
13)Passamonti F, et al:Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117:755-761, 2004
14)Tseng EY, et al:Angiographic embolization for epistaxis:a review of 114 cases. Laryngoscope 108:615-619, 1998
15)Christensen NP, et al:Arterial embolization in the management of posterior epistaxis. Otolaryngol Head Neck Surg 133:748-753, 2005